MicrobiologyAntiviral ResearchPeer-reviewed
Dihydroartemisinin inhibits Epstein-Barr virus reactivation and replication targeting lytic proteins: insights for drug repurposing
This study identifies dihydroartemisinin as a repurposed drug that inhibits EBV reactivation and replication by targeting the lytic protein BZLF1.
DOI 10.1016/j.antiviral.2026.106513